Scholars Central

Research articlePublished 3 May 2019

Effacing diseases with Antisense Oligonucleotides

Authors: David Banji, Otilia J. F. Banji, Jyothi Pinnapureddy

Der Pharmacia Lettre

Volume 2 · Issue 2 · Pages 393–407

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Anti-sense oligonucleotides are short, modified single stranded DNA or RNA that hybridize with target mRNA and inhibit synthesis of encoded peptide. This inhibition is achieved by either degradation of target mRNA by RNase enzyme or by blocking translation. Novel therapeutics are the need of the hour to combat newer diseases. High specificity and lower costs are core issues in the development of novel therapeutic agents. Antisense oligonucleotides meet all these criteria and are also effective in targeting a number of diseases. The presence of formivirsen in the market has provided an impetus for development of new antisense oligonucleotides and several others are in the pipeline. This review focuses on various facets of antisense oligonucliotides.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Der Pharmacia Lettre.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDer Pharmacia Lettre
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “David Banji”
  • BylineArticles whose byline prints “Otilia J. F. Banji”
  • BylineArticles whose byline prints “Jyothi Pinnapureddy”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels